Humana (NYSE:HUM) Given New $353.00 Price Target at Royal Bank of Canada

Humana (NYSE:HUM) had its price objective decreased by research analysts at Royal Bank of Canada from $415.00 to $353.00 in a research note issued on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the insurance provider’s stock. Royal Bank of Canada’s price objective suggests a potential upside of 13.69% from the company’s current price.

A number of other analysts have also recently weighed in on HUM. Deutsche Bank Aktiengesellschaft cut Humana from a “buy” rating to a “hold” rating and cut their price target for the company from $595.00 to $360.00 in a research note on Thursday, January 25th. Barclays cut their price target on Humana from $356.00 to $310.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 2nd. Wells Fargo & Company cut their price target on Humana from $413.00 to $350.00 and set an “overweight” rating on the stock in a research note on Monday, April 8th. StockNews.com cut Humana from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 26th. Finally, Oppenheimer cut their target price on Humana from $415.00 to $370.00 and set an “outperform” rating on the stock in a research report on Thursday. Eleven investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $433.74.

Humana Trading Down 1.7 %

Shares of HUM traded down $5.48 during midday trading on Thursday, hitting $310.50. 858,586 shares of the stock were exchanged, compared to its average volume of 1,991,986. The firm has a market cap of $37.46 billion, a P/E ratio of 15.61, a P/E/G ratio of 1.92 and a beta of 0.45. The stock has a fifty day simple moving average of $329.24 and a 200 day simple moving average of $396.94. Humana has a 52-week low of $299.23 and a 52-week high of $541.21. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.59 and a current ratio of 1.59.

Humana (NYSE:HUM) last released its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.12 by $1.11. Humana had a return on equity of 19.44% and a net margin of 2.34%. The firm had revenue of $29.61 billion during the quarter, compared to analyst estimates of $28.52 billion. During the same period last year, the business posted $9.38 earnings per share. Humana’s revenue was up 10.7% compared to the same quarter last year. On average, research analysts anticipate that Humana will post 16.06 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Jorge S. Mesquita purchased 545 shares of the stock in a transaction that occurred on Tuesday, February 20th. The shares were purchased at an average price of $367.09 per share, with a total value of $200,064.05. Following the completion of the acquisition, the director now directly owns 2,578 shares in the company, valued at approximately $946,358.02. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.32% of the company’s stock.

Institutional Investors Weigh In On Humana

A number of institutional investors have recently added to or reduced their stakes in HUM. Exchange Traded Concepts LLC boosted its holdings in Humana by 103.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 2,883 shares of the insurance provider’s stock valued at $1,403,000 after purchasing an additional 1,463 shares in the last quarter. Caprock Group LLC boosted its stake in shares of Humana by 3.6% during the 3rd quarter. Caprock Group LLC now owns 1,421 shares of the insurance provider’s stock worth $693,000 after acquiring an additional 50 shares in the last quarter. UMB Bank n.a. boosted its stake in shares of Humana by 2.8% during the 3rd quarter. UMB Bank n.a. now owns 805 shares of the insurance provider’s stock worth $392,000 after acquiring an additional 22 shares in the last quarter. Czech National Bank boosted its stake in shares of Humana by 46.4% during the 3rd quarter. Czech National Bank now owns 21,656 shares of the insurance provider’s stock worth $10,536,000 after acquiring an additional 6,866 shares in the last quarter. Finally, Aaron Wealth Advisors LLC purchased a new stake in shares of Humana during the 3rd quarter worth approximately $213,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.